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β2-1 fructans are prebiotics and, as such, may modulate some aspects of immune
function. Improved immune function could enhance the host’s ability to respond to infec-
tions. There is limited information on the effects of β2-1 fructans on immune responses 
in humans. The objective of the study was to determine the effect of a specific combi-
nation of long-chain inulin and oligofructose (Orafti® Synergy1) on immune function in
middle-aged humans, with the primary outcome being response to seasonal influenza
vaccination. Healthy middle-aged humans (45–63 years of age) were randomly allocated 
to consume β2-1 fructans in the form of Orafti® Synergy1 (8 g/day; n = 22) or malto-
dextrin as control (8 g/day; n = 21) for 8 weeks. After 4 weeks, participants received
the 2008/2009 seasonal influenza vaccine. Blood and saliva samples were collected
prior to vaccination and 2 and 4 weeks after vaccination. They were used to measure
various immune parameters. The primary outcome was the serum concentration of
anti-vaccine antibodies. Serum antibody titers against the vaccine and vaccine-specific 
immunoglobulin concentrations increased post-vaccination. Antibodies to the H3N2-like 
hemagglutinin type 3, neuraminidase type 2-like strain were higher in the Synergy1 group 
(P = 0.020 for overall effect of treatment group), as was serum vaccine-specific IgG1
2 weeks post-vaccination (P = 0.028 versus control). There were no other differences
between groups in antibody titers or anti-vaccine immunoglobulin concentrations, in
blood immune cell phenotypes, or in a range of immune parameters. It is concluded
that Orafti® Synergy1, a combination of β2-1 fructans, can enhance some aspects of
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Abbreviations: BMI, body mass index; BSA, bovine serum albumin; CD, cluster of differentiation; CFSE, carboxyfluorescein 
diacetate succinimidyl ester; Con A, concanavalin A; ELISA, enzyme-linked immunosorbent assay; HI, hemagglutination 
inhibition; IFN, interferon; Ig, immunoglobulin; IL, interleukin; MFI, mean fluorescence intensity; NK, natural killer; OD, 
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introduction
The prebiotic effect is defined as the selective stimulation of 
the growth and/or activity of gut microbes that confer health 
benefits to the host (1), as discussed elsewhere (2). β2-1 fructans 
are considered to be prebiotics. Inulin is a naturally occurring 
β2-1 fructan. Inulin can vary in chain length and can be hydro-
lyzed to shorter chain length oligofructose molecules. Orafti® 
Synergy1 (referred to hereafter as Synergy1) contains a 50:50 
(w/w) mixture of long-chain inulin and oligofructose. β2-1 
fructans have been reported to modulate the intestinal micro-
biota (3–9), specifically increasing the numbers of bifidobacteria 
and lactobacilli. It is thought that bifidobacteria and lactobacilli 
influence the host immune system, improving its function (10). 
So far, there is no consensus on the best method to assess immune 
function in human studies (11–15). Vaccination is a controlled 
way to expose the immune system to a specific amount and type 
of antigen. It has been proposed that the body’s response to this 
antigenic exposure is the most relevant way in which to assess the 
functioning of the immune system, in the absence of an infectious 
challenge (12–15).
Several studies have been performed using response to vac-
cination as a tool to examine the effect of β2-1 fructans upon 
human immune function (16–26); although in most cases, the 
β2-1 fructans were used in combination with other potentially 
bioactive ingredients. Of these 11 studies, 4 found an effect of β2-1 
fructans upon the vaccine-specific response (16, 17, 19, 20), while 
7 did not (18, 21–26). These studies were performed in infants or 
children (16, 18, 21, 23–26) or in elderly adults (17, 19, 20, 22). 
Of the four studies carried out in the elderly, only one used β2-1 
fructans alone (17), the remaining studies used supplements also 
containing vitamins, minerals, fats, or probiotics (19, 20, 22). 
Thus, there are few studies of β2-1 fructans alone on the immune 
response to vaccination in adult humans and there are no studies 
in middle-aged humans who may be considered to be a target 
group of consumers.
The aim of this study was to evaluate the effect of Synergy1 
(8 g/day) on immune function in middle-aged humans using a 
double-blind randomized controlled trial design with the primary 
outcome being response to seasonal influenza vaccination deter-
mined as serum anti-vaccine antibody concentrations. We have 
previously reported that 4 weeks supplementation with Synergy1 
(8 g/day) increased total and relative numbers of bifidobacteria in 
feces, but that there was no effect on a range of immune param-
eters measured in the absence of an in vivo immune challenge (9). 
We hypothesized that Synergy1 will enhance the serum antibody 
response to seasonal influenza vaccination.
Participants, Materials, and Methods
Participants
Participants (n = 49) were recruited via posters, word of mouth, 
e-mail, and newspaper/magazine advertisements. Both men and 
women were recruited. The inclusion criteria were as follows: age 
between 45 and 65  years; body mass index (BMI) between 20 
and 32 kg/m2; not consuming prebiotic or probiotic supplements, 
drinks, or foods; in general good health; no antibiotic use in the 
2 months prior to entering the study or during the study; and not 
having been vaccinated with the 2008/2009 seasonal influenza 
vaccine. The exclusion criteria were as follows: being type 1 or 
type 2 diabetic; displaying manifestations of allergy (asthma, hay-
fever, or dermatitis) or being treated for these; being egg allergic; 
use of any prescribed medication (unless deemed acceptable by 
the principle investigator); suffering from any infectious illness or 
chronic gastrointestinal problem (e.g., irritable bowel syndrome, 
inflammatory bowel disease, cancer); recent blood donation; 
participation in another clinical trial; consuming vitamin, fish 
oil, evening primrose oil, or mineral supplements. The 2008/2009 
vaccine included an A/Brisbane/59/2007 (H1N1)-like, an A/
Brisbane/10/2007 (H3N2)-like, and a B/Florida/4/2006 (B)-like 
virus strain. Although seasonal influenza vaccines always include 
H1N1-, H3N2- and B-like virus strains, the specific strains used 
in the 2008/2009 vaccine had not been used previously (27). 
The Southampton and South West Hampshire Local Research 
Ethics Committee approved the study (09/H0504/2) and clinical 
governance was provided by Southampton University Hospitals 
NHS Trust Research and Development. All participants pro-
vided written informed consent. The study was registered at 
www.clinicaltrials.gov as NCT00898599.
study Design and intervention
The study was a randomized, double-blind, controlled trial, with 
an 8-week intervention period; only data from the final 4 weeks 
are reported here. Data from the first 4 weeks of the interven-
tion (i.e., prior to vaccination) have been reported elsewhere, 
and there was no effect on any immune parameter measured, 
despite an increase in the number of bifidobacteria in feces (9). 
Allocation to group [Synergy1 (n = 25); control (maltodextrin; 
n =  24)] was done by random selection of a sealed envelope 
containing a treatment code. Unblinding did not occur until after 
completion of all statistical analyses. Following randomization, 
participants underwent a 2-week run-in period, during which 
they limited their consumption of prebiotic and probiotic con-
taining foods, and these restrictions continued throughout the 
study. Upon completion of this run-in, participants began the 
8-week period of supplementation. Synergy1 and maltodextrin 
were provided as powders within coded, sealed paper sachets 
(4 g/sachet) by Beneo-Orafti, and were identical in appearance 
and packaging, except for the labeling (A or B). Participants 
were asked to consume two sachets per day (one in the morn-
ing and one in the evening yielding a total daily intake of 8 g) 
by stirring the contents into a glass of water. Participants were 
given enough sachets to cover the period of the study and were 
asked to return all sachets (used and unused) in order to assess 
compliance. Participants attended the Wellcome Trust Clinical 
Research Facility, Southampton General Hospital four times 
during the study (weeks 0, 4, 6, and 8). At week 4, they received 
the 2008/2009 seasonal influenza vaccination (Imuvac; Solvay 
Biologicals, Southampton, UK) by intramuscular injection. In 
this report, data from the final 4 weeks of the intervention period 
(i.e., weeks 4, 6, and 8) are presented. Blood and saliva samples 
were collected at each time point. Preparation of serum, plasma, 
and peripheral blood mononuclear cells (PBMCs) was described 
previously (9).
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assessment of Blood immune cell Phenotypes 
and natural Killer cell activity
Blood immune cell phenotypes were determined by flow cytom-
etry after staining with relevant fluorescently labeled monoclonal 
antibody pairs; procedures were performed, as described 
elsewhere (9). Killing of the K562 (target) cell line by PBMCs 
was used to assess natural killer (NK) cell activity (9). Killing 
by unstimulated and interleukin (IL)-2-stimulated PBMCs was 
determined. Specific target cell lysis was calculated as (% total 
target cell death − % spontaneous target cell death).
Measurement of immunoglobulin 
concentrations in saliva and serum
Salivary secretory IgA (sIgA) and serum total immunoglobulin 
(Ig)A, IgM, and IgG concentrations were measured by enzyme-
linked immunosorbent assay (ELISA) (9).
assessment of T-cell responses
Activation of cluster of differentiation (CD)4+ T cells was assessed 
by appearance of CD69 on the cell surface following stimulation 
for 24 h with the polyclonal T cell mitogen concanavalin A (Con 
A) at a final concentration of 5 μg/mL (9). The percentage of cells, 
which had undergone activation (i.e., CD3+CD4+CD69+) as well 
as the MFI of CD69 expression on these cells, was determined. 
The concentrations of the cytokines IL-2, IL-4, IL-6, IL-10, tumor 
necrosis factor (TNF)-α, and interferon (IFN)-γ were measured in 
the culture medium, as described elsewhere (9). The proliferation 
of lymphocytes was determined by dilution of carboxyfluorescein 
diacetate succinimidyl ester (CFSE) over 168 h following Con A 
stimulation of PBMC cultures, as described elsewhere (9).
Measurement of serum Vaccine-specific 
antibodies by hemagglutination inhibition assay
Vaccine-specific antibodies in serum were measured by 
ViroClinics B.V. (Rotterdam, The Netherlands), using a hemag-
glutination inhibition (HI) assay, based on the principle that 
influenza viruses agglutinate erythrocytes of some avian species, 
and incubation of the virus with virus-specific antibodies (present 
in serum of participants who have been vaccinated) prior to this 
agglutination reaction will inhibit the agglutination. Antibody 
titers <10 HI units were set to 5. Seroconversion is defined as the 
percentage of participants showing at least a fourfold increase in 
antibody titer and seroprotection as an antibody titer of ≥40 HI 
units (28).
Measurement of antibody class-specific, 
Vaccine-specific antibodies by elisa
Antibody class-specific, vaccine-specific antibodies were meas-
ured by a modification of the procedure described by Olivares 
et  al. (29). Ninety-six-well Maxisorb ELISA plates (Fischer 
Scientific, Loughborough, UK) were coated with a 500  ng/mL 
solution of vaccine (Solvay Biologicals) in coating buffer (0.5M 
Na2CO3 in distilled water), 100 μL/well, and incubated overnight 
at 4°C. Plates were washed three times with 250 μL wash solution 
[50 mM TRIS (Aldrich), 0.14M NaCl (Fischer), 1% bovine serum 
albumin (BSA) (Sigma), 0.2% Tween-20 (Sigma), in distilled 
water]. One hundred microliters of block buffer [5% BSA in 
phosphate buffered saline (PBS)] were added to each well and 
incubated at 37°C for 1 h. Plates were washed three times. Plasma 
(100 μL undiluted for IgA, IgD, and IgM and diluted 1:100 in 
PBS for IgG1) was added to each well, and incubated at room 
temperature for 1 h. Plates were washed three times. Antibody 
(100 μL mouse anti-human IgA, IgD, IgG1, or IgM; 0.5 mg/mL; 
AbD Serotec) was added to each well, and incubated at room tem-
perature for 1 h. Plates were washed three times. Goat anti-mouse 
IgG (H/L):horseradish peroxidize (100 μL; AbD Serotec; diluted 
1:10,000 in PBS) was added to each well, and incubated at room 
temperature for 1 h. Plates were washed three times. Staining was 
performed by adding 100 μL of 3,3′,5,5′ tetramethylbenzidine 
(Sigma) and incubating at room temperature in the dark for 
20 min. One hundred microliters of stop solution (Sigma) were 
added, and plates read on a plate reader (Thermo Labsystems, 
Original Multiskan) at 450  nm. Data are expressed as optical 
density (OD) units.
statistical analysis
Analysis was performed by two-factor ANOVA in the first 
instance (fixed factors: time and treatment group); data for 
vaccine-specific antibody titers were log transformed prior to 
analysis. Where appropriate, comparisons between groups were 
performed using independent samples t-test, Mann–Whitney 
test, Chi squared test, or Fisher’s exact test depending upon the 
nature of the data. Comparisons between time points within a 
group were made using paired t-test or Wilcoxon Signed Rank 
test depending upon the nature of the data. All analyses were 
performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) 
and in all cases a value for P < 0.05 was taken to indicate statistical 
significance.
results
Participant characteristics and compliance
Forty-nine participants were recruited and randomized (n = 24 
in the maltodextrin group; n = 25 in the Synergy1 group) and 43 
of these completed the study (n = 21 in the maltodextrin group; 
n = 22 in the Synergy1 group). The characteristics of these partici-
pants, as shown in Table 1, did not differ between the two groups. 
As reported previously (9) compliance, assessed by returned 
unused sachets, was good (median 100% in both groups) and 
Synergy1 increased fecal bifidobacteria numbers.
Blood immune cell Phenotypes
There were some significant effects of group, but no significant 
effects of time or significant group  ×  time interactions, for 
TaBle 1 | characteristics according to study group.
Maltodextrin group synergy1 group
n 21 22
Age (years); mean (range) 56 (45–63) 54 (45–62)
Male:female 8:13 3:19
BMI (kg/m2); mean (range) 25.0 (17.7–33.8) 25.7 (19.4–33.3)
Data are shown for participants who completed the study.
There were no significant differences between groups.
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circulating immune cell subsets (Table S1 in Supplementary 
Material). The percentages of CD3+CD8+ and CD8+ cells were 
higher in the Synergy1 group (two-factor ANOVA effect of 
group P < 0.001 for both) but were not affected by vaccination. 
As a consequence of the higher percentage of CD8+ cells in the 
Synergy1 group, this group had a lower CD4:CD8 ratio (two-
factor ANOVA effect of group P = 0.002).
natural Killer cell activity
Natural killer cell activity toward K562 cells was enhanced by 
pre-incubation with IL-2 (Table S2 in Supplementary Material). 
However, there were no significant effects of group or time and 
no significant group  ×  time interactions for NK cell activity 
with or without IL-2 pre-incubation (Table S2 in Supplementary 
Material).
serum Total immunoglobulin and salivary iga 
concentrations
There were no significant effects of group, one significant effect of 
time, and no significant group × time interactions for serum total 
IgA, IgG, and IgM concentrations (Table S3 in Supplementary 
Material). There was a significant effect of group but no signifi-
cant effect of time and no significant group × time interaction for 
salivary sIgA (two-factor ANOVA effect of group P =  0.008); 
concentrations were lower in the Synergy1 group (Table S3 in 
Supplementary Material). When salivary sIgA concentrations 
were adjusted for total salivary protein, there was no longer a 
significant effect of group (Table S3 in Supplementary Material).
T cell activation, Proliferation, and cytokine 
Production in response to Polyclonal stimulation
Data for T cell activation, proliferation, and cytokine produc-
tion, all in response to the polyclonal T cell mitogen Con A, are 
shown in Table 2. Con A stimulation increased the percentage 
of CD69 positive CD3+CD4+ cells and increased the level of 
CD69 expression on those cells (i.e., MFI) (Table 2). Con A also 
increased the percentage of proliferating T cells and decreased 
CFSE MFI indicative of dilution of the dye (Table  2). Finally, 
Con A increased the production (i.e., the concentration in the 
culture medium) of all six cytokines assessed (Table 2). Increases 
were approximately 4-fold for percentage of CD69+ cells (from 
approximately 14 to 55%), approximately 4.5-fold for percent-
age of proliferating cells (from approximately 15 to 70%), and 
approximately 2- to 260-fold for cytokine production depend-
ing upon the cytokine (see Table 2). There were no significant 
effects of group, one significant effect of time, and no significant 
group × time interactions for T cell activation or T cell prolifera-
tion (Table 2). There were no significant effects of group or time 
and no significant group × time interactions for IL-2, IL-6, IL-10, 
TNF-α, or IFN-γ production in the absence of Con A or IL-2 or 
IL-10 production in the presence of Con A (Table 2). There was 
a significant effect of group on production of IL-4 in the absence 
of Con A (lower in the Synergy1 group, P = 0.005) and on pro-
duction of IL-4 (lower in the Synergy1 group, P = 0.032), IL-6 
(higher in the Synergy1 group, P = 0.032), TNF-α (higher in the 
Synergy1 group, P = 0.024), and IFN-γ (higher in the Synergy1 
group, P = 0.007) in the presence of Con A. The Th1/Th2 ratio 
was calculated using the concentrations of the prototypical T 
helper (Th)1-type (IFN-γ) and Th2-type (IL-4) cytokines. There 
was a significant effect of group, but not of time and no significant 
group × time interaction, on the ratio. The ratio was higher in the 
Synergy1 group (P = 0.004).
Vaccine strain-specific antibody response
Serum vaccine-specific antibody concentrations are shown in 
Table 3. There was a significant effect of time on the concentra-
tions of all three vaccine-specific antibodies (two-factor ANOVA 
effect of time P < 0.001 for all three antibodies), such that they 
were higher at weeks 6 and 8 than at week 4. There was a significant 
effect of group on the concentration of antibodies to the H3N2-
like strain (P = 0.020), but there was no effect of group on the 
concentrations of antibodies to the H1N2- or the B-like strains. 
The antibody response to the H3N2-like strain was greater in the 
Synergy1 group.
In the maltodextrin group, seroconversion rates to the H1N1-
like, H3N2-like, and B-like strains at week 6 were 85, 70, and 80%, 
respectively, while in the Synergy1 group, the rates were 85, 90, and 
80%, respectively. In the maltodextrin group, seroprotection rates 
to the H1N1-like, H3N2-like, and B-like strains at week 6 were 
80, 72, and 75%, respectively, while in the Synergy1 group, the 
rates were 80, 91, and 77%, respectively. These rates of serconver-
sion and seroprotection were not significantly different between 
groups, although they were numerically higher in response to the 
H3N2-like strain in the Synergy1 group.
immunoglobulin class-specific antibodies to 
the Vaccine antigen
Immunoglobulin class-specific antibodies to the vaccine antigen 
were measured according to the method described by Olivares 
et al. (29) and, in the absence of standards for these antibodies, 
data are expressed as OD units (Table 4); OD units are directly 
related to concentration. There was a significant effect of time on 
serum vaccine-specific IgM, IgG1, and IgD OD units and a trend 
to an effect on vaccine-specific IgA OD units (Table 4). In general, 
these were higher 2 and 4 weeks post-vaccination than prior to 
vaccination. There was no significant effect of group on vaccine-
specific IgA, IgM, or IgD OD units. However, vaccine-specific 
IgG1 OD units were higher in the Synergy1 group (two-factor 
ANOVA effect of group P = 0.018). At week 6, vaccine-specific 
IgG1 OD units were higher in the Synergy1 group compared to 
the maltodextrin group (P = 0.028, independent T-test). Between 
week 4 and 6, the increase in specific IgG1 OD units was greater 
in the Synergy1 group compared to the maltodextrin group 
(P = 0.036, independent T-test).
Discussion
Several human studies have investigated the effect of β2-1 
fructans upon the antibody response following vaccination, 
and some of these studies have reported an improvement in this 
response (16, 17, 19, 20), while others have not (18, 21–26). In 
these studies, the prebiotic has often been combined with other 
nutrients (19–26). Furthermore, these previous studies have been 
conducted in children (16, 18, 21, 23–26) or in elderly adults 
TaBle 3 | Vaccine strain-specific antibody response in participants in the maltodextrin and synergy1 groups.
Maltodextrin group synergy1 group P*
Week 4 Week 6 Week 8 Week 4 Week 6 Week 8 group Time group × Time
H1N1 5.3 (1.6) 1103a (3398) 948a (3342) 14.8 (34.3) 518a (1103) 394a (1081) 0.756 <0.001 0.837
H3N2 16.2 (34.1) 4338a (8287) 2702a (6147) 71.9 (277.1) 6234a (8352) 6479a (9035) 0.020 <0.001 0.428
B 6.4 (4.5) 139a (187) 149a (221) 10.7 (17.6) 276a (472) 172a (267) 0.179 <0.001 0.851
Data are mean (SD) hemagglutination inhibition units for n = 21 in the maltodextrin group and n = 22 in the Synergy1 group.
*Value for P from two-factor ANOVA (fixed factors: group, time).
aSignificantly different from week 4 (all P < 0.001).
TaBle 2 | Measures of T cell function in response to con a in participants in the maltodextrin and synergy1 groups.
Maltodextrin group synergy1 group P*
cona Week 4 Week 6 Week 8 Week 4 Week 6 Week 8 group Time group × Time
T cell activation
% CD3+CD4+CD69+ (%) − 14.9 (12.6) 12.5 (9.6) 11.5 (8.1) 13.5 (6.2) 15.1 (6.4) 14.9 (9.5) 0.357 0.884 0.439
CD69 MFI − 45.4 (11.7) 40.1 (10.7) 38.7 (11.5) 45.5 (13.8) 43.3 (10.0) 39.6 (9.8) 0.506 0.049 0.817
% CD3+CD4+CD69+ (%) + 57.4 (16.1) 55.9 (11.9) 53.3 (16.1) 55.7 (12.6) 52.5 (13.1) 50.6 (14.1) 0.312 0.347 0.964
CD69 MFI + 101.0 (48.4) 91.9 (33.0) 88.5 (31.7) 92.3 (27.5) 88.4 (25.6) 82.9 (26.5) 0.326 0.335 0.939
T cell Proliferation
% Proliferating cells (%) − 17.8 (21.9) 11.6 (5.5) 15.7 (17.9) 16.5 (19.6) 13.1 (14.1) 13.7 (16.3) 0.364 0.774 0.483
CFSE MFI − 736.8 (316.5) 803.2 (233.2) 661.3 (444.1) 773.1 (292.9) 778.2 (299.9) 815.2 (335.6) 0.862 0.464 0.898
% Proliferating cells (%) + 66.4 (24.3) 76.6 (15.4) 64.9 (26.6) 69.2 (23.9) 73.2 (20.5) 69.4 (25.1) 0.609 0.516 0.542
CFSE MFI + 285.4 (326.9) 168.3 (84.9) 258.3 (345.1) 220.2 (163.5) 214.8 (243.1) 208.1 (158.5) 0.769 0.280 0.746
T cell cytokine  
production (pg/ml)
IL-2 − 2.1 (1.4) 1.9 (0.9) 1.7 (0.7) 1.9 (0.6) 2.1 (1.9) 1.9 (1.1) 0.887 0.629 0.674
IL-4 − 2.1 (1.0) 2.0 (0.9) 1.9 (1.0) 1.6 (0.5) 1.6 (0.4) 1.6 (0.7) 0.005 0.905 0.768
IL-6 − 3036 (3337) 2112 (2275) 2323 (3058) 2639 (3145) 3856 (3415) 3108 (2937) 0.212 0.926 0.299
IL-10 − 16.2 (10.1) 12.9 (9.4) 23.9 (46.9) 18.3 (18.5) 24.7 (23.2) 24.9 (37.3) 0.319 0.471 0.625
TNF-α − 37.3 (31.0) 42.9 (76.1) 41.7 (43.3) 22.7 (16.8) 60.7 (63.9) 64.9 (75.3) 0.384 0.113 0.257
IFN-γ − 6.4 (4.4) 4.4 (2.3) 4.1 (1.3) 4.6 (2.3) 11.1 (23.6) 3.7 (0.6) 0.400 0.216 0.117
IL-2 + 97.2 (81.1) 85.7 (81.2) 63.4 (48.7) 109.8 (68.5) 73.7 (55.3) 86.2 (66.1) 0.525 0.125 0.493
IL-4 + 12.2 (9.1) 11.9 (9.7) 10.1 (7.9) 10.8 (15.0) 6.3 (3.8) 6.5 (3.1) 0.032 0.249 0.563
IL-6 + 7235 (5105) 4913 (4058) 4588 (6110) 8310 (3876) 6003 (4371) 8944 (5095) 0.032 0.173 0.304
IL-10 + 76.2 (42.7) 74.2 (66.2) 75.1 (91.8) 92.7 (75.4) 83.1 (119.8) 69.1 (36.1) 0.639 0.764 0.795
TNF- α + 333.9 (232.6) 270.3 (229.6) 271.5 (261.7) 434.4 (449.1) 388.9 (414.0) 486.5 (439.5) 0.024 0.740 0.730
IFN-γ + 1056 (1029) 663 (732) 724 (985) 2081 (3127) 1604 (2887) 1754 (2006) 0.007 0.594 0.994
Th1/Th2 ratioa
− 3.1 (1.7) 2.5 (1.2) 2.4 (0.6) 3.1 (1.4) 6.8 (12.8) 2.5 (0.5) 0.140 0.184 0.135
+ 151.3 (222.4) 102.5 (177.3) 83.4 (97.7) 248.4 (282.4) 181.5 (211.8) 297.3 (369.6) 0.004 0.513 0.397
Data are mean (SD) for n = 21 in the maltodextrin group and n = 22 in the Synergy1 group.
*Value for P from two-factor ANOVA (fixed factors: group, time).
aCalculated using the concentrations of IFN-γ and IL-4.
IFN, interferon; IL, interleukin; MFI, median fluorescence intensity; TNF, tumor necrosis factor.
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(17, 19, 20, 22). It is necessary to identify the functional effects 
β2-1 fructans in the absence of other interventions, and also 
to assess whether effects occur in middle-aged humans, as this 
group is considered a target group of consumers. In the current 
study, a specific combination of long-chain inulin and oligofruc-
tose (Synergy1) was evaluated.
The present study investigated the effect of Synergy1 at 8 g/
day for 4  weeks prior to, and for 4  weeks following, seasonal 
influenza vaccination on a range of measures of immune 
function in healthy middle-aged participants. A randomized 
controlled parallel study design was used with the digestible 
carbohydrate maltodextrin as the control. Synergy1 increased 
fecal bifidobacteria numbers within 4 weeks (9) confirming its 
prebiotic effect. However, there were no alterations in any of 
the immune markers measured in the absence of an exogenous 
immune challenge (i.e., prior to vaccination) (9). It was antici-
pated that some improvements in immune function would be 
observed following a controlled immune challenge, such as a 
seasonal influenza vaccination after supplementation with 
Synergy1. A range of measures was used in order to identify 
a potential effect of Synergy1 on immune function. The activ-
ity of NK cells was assessed because these cells have a key role 
in anti-viral immunity and their activity has been shown to 
be enhanced 2 and 4 weeks following seasonal influenza vac-
cination (30), although this enhancement was not seen in the 
current study. Responses of PBMCs to the T cell mitogen Con A 
were assessed. It is important to note that Con A is a polyclonal 
T cell stimulant and responses to such stimulants may have 
TaBle 4 | serum vaccine-specific immunoglobulins in participants in the maltodextrin and synergy1 groups.
Maltodextrin group synergy1 group P*
Week 4 Week 6 Week 8 Week 4 Week 6 Week 8 group Time group × Time
Specific IgA 1.72 (0.88) 2.20 (1.00) 2.00 (0.97) 1.66 (0.62) 2.03 (0.79) 1.88 (0.82) 0.443 0.076 0.961
Specific IgM 1.75 (0.67) 2.73 (0.73) 2.59 (0.70) 1.85 (0.62) 3.03 (0.63) 2.74 (0.51) 0.133 <0.001 0.759
Specific IgG1 1.18 (0.39) 1.88 (0.57) 2.03 (0.63) 1.26 (0.48) 2.25a (0.48) 2.24 (0.56) 0.018 <0.001 0.441
Specific IgD 0.47 (0.13) 0.58 (0.14) 0.60 (0.14) 0.51 (0.25) 0.58 (0.19) 0.60 (0.22) 0.755 0.012 0.860
Data are mean (standard deviation) optical density units for n = 21 in the maltodextrin group and n = 22 in the Synergy1 group.
*Value for P from two-factor ANOVA (fixed factors: group, time).
aSignificantly different from control (maltodextrin) group (P = 0.028).
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only limited relation to the vaccination response. However, an 
impaired ex vivo response to mitogens has been described to 
occur 2 weeks following seasonal influenza vaccination, with 
the impairment being associated with a lower vaccine-induced 
antibody response (31). Again this decline was not seen in the 
current study. Ex vivo PBMC responses to vaccine stimulation 
were also assessed in the current study but responses were weak 
and highly variable (data not shown).
Few differences were seen between groups in most immune 
outcomes measured, including the blood immune cell pro-
file, a marker of mucosal immunity (salivary sIgA), and an 
innate immune response (NK cell activity). T cell responses 
to a polyclonal T cell stimulant (Con A) were little affected, 
although the Th1-type response was higher in the Synergy1 
group. However, two important and novel observations were 
made. First, the antibody response to the H3N2-like strain of 
the vaccine was higher in the Synergy1 group. Additionally, 
the seroconversion and seroprotection rates to this strain of the 
virus tended to be enhanced with Synergy1. Second, the IgG1-
specific antibody response to the vaccine (as measured in OD 
units) was enhanced in the Synergy1 group, and this response 
appeared to occur more quickly as by week 2 levels had reached 
a maximum in the Synergy1 group but were still rising in the 
maltodextrin group. Therefore, Syngery1 was able to enhance 
some aspects of the antibody response to vaccination, which 
is considered to be the most valid marker of immune function 
in humans (13–15).
The enhancement in antibody response to the H3N2-like 
strain and in vaccine-specific IgG1 suggests that Synergy1 
does impact on the host immune system, and this may be the 
result of the change in fecal (and so gut) microbiotia described 
previously (9). It is important to identify which aspect of 
the immune response is affected by Synergy1. The current 
study focused on identifying whether Synergy1 affected the 
profile of immune cells in the bloodstream, NK cell activity, 
and the functional responses of T lymphocytes (activation, 
proliferation, and cytokine production)-induced ex vivo using 
the polyclonal T cell stimulant Con A. Con A-induced strong 
activation, proliferation, and cytokine responses. The activa-
tion and proliferative responses of T cells were not enhanced 
by Synergy1, but Con A-induced production of some cytokines 
was greater with Synergy1, suggestive of an enhanced Th1-type 
response. This may underlie the enhanced antibody response 
seen. It is also possible that Synergy1 may have affected antigen 
presenting cells and the processes of antigen uptake, processing 
and presentation or B cells and the process of antibody produc-
tion. These aspects were not investigated here and should be 
examined in future studies.
The observation that Synergy1 increased the concentration 
of antibodies to only one of the three strains of the vaccine 
is consistent with a number of earlier studies with different 
nutritional and pharmacological interventions. For example, 
Langkamp-Henken et al. (19) reported that a nutritional for-
mula containing antioxidants, zinc, selenium, β2-1 fructans, 
and structured triacylglycerol resulted in a higher antibody 
response to the H1N1-like strain of the influenza virus in 
elderly subjects, with no effect on the antibody response to 
the H3N2-like or B-like strains. Boge et al. (32) found that a 
mix of probiotics resulted in a higher antibody response to 
the B-like strain at 3, 6, and 9 weeks post-vaccination but with 
no significant effect on the response to the H1N1-like or the 
H3N2-like strains. Davidson et al. (33) showed that a mixture 
of Lactobacillus casei GG and β2-1 fructans resulted in a greater 
response to the H3N2-like stain of the vaccine, with no effect on 
the response to the H1N1-like or B-like strains. Administration 
of the steroid hormone dehydroepiandrosterone sulfate 
resulted in a higher response to the H3N2-like strain of the 
vaccine in healthy older subjects with no effect on the response 
to the H1N1-like or B-like strains (34). Furthermore, corticos-
teroid treatment of asthmatic children and adults impaired the 
antibody response to the B-like strain but not to the H1N1-like 
or H3N2-like strains of the vaccine (35). The anti-influenza 
agent zanamivir resulted in a lower antibody response to the 
H1N1-like strain of the vaccine in healthy volunteers compared 
with a placebo treatment, but did not affect the response to 
the H3N2-like or B-like strains (36). Why these different 
nutritional and pharmacological interventions consistently 
influence the response to only one of the three virus strains in 
the influenza vaccine is not clear, but this may relate to precise 
nature of the immune interactions between the vaccine antigen 
and the host immune system and how these interactions are 
influenced by the intervention.
Strengths of the current study were the use of a rand-
omized, controlled, double-blind design; the high compli-
ance of participants to the intervention (median 100%); the 
low rate of drop-out (12%); the confirmation that Synergy1 
modified the fecal microbiota (9); and the follow-up at 
two time-points post-vaccination. However, the study does 
have limitations. First, the relatively small sample size may 
have limited the ability to identify clear effects of Synergy1. 
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Second, the subjects studied were healthy and middle aged; 
although they represent a target group for prebiotics the 
findings cannot be generalized to the elderly or to individuals 
with disease. Third, as indicated above, we did not examine 
some aspects of the immune system involved in the response 
to vaccination.
In conclusion, after supplementation with Synergy1 (8  g/
day for 4 weeks prior to vaccination and 4 weeks post-vaccina-
tion), there was a higher antibody response to the H3N2-like 
strain of the vaccine and an enhanced IgG1-specific antibody 
response to the vaccine. Most other immune responses 
assessed were not affected, although the Synergy1 group had 
higher Th1-type responses ex vivo. Thus, β2-1 fructans in the 
form of Synergy1 can enhance some aspects of the immune 
response in healthy middle-aged adults, but this is not a global 
effect. However, this effect is relatively modest and its biologi-
cal significance is not clear.
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